Skip to content

Antifungal Potential of Moringa Olifera Against Otomycosis

Antifungal Potential of Moringa Olifera-loaded Nanoparticles Against Otomycosis; Preparation, Characterization, and Clinical Evaluation

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04768829
Enrollment
10
Registered
2021-02-24
Start date
2021-02-18
Completion date
2021-12-01
Last updated
2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Otomycosis

Brief summary

patients with Otomycosis were recognized by an ENT specialist. 20 patients were distributed randomly into two groups. The first group will be treated with Nystatin ear drops twice daily. The second group will be treated with Moringa ear drops. patients will be examined endoscopically by the ENT specialist. patient's swabs will be isolated and analyzed by ELISA.

Detailed description

Inclusion criteria: (1) Otomycosis . Exclusion criteria: 1. tympanic membrane perforation; 2. concurrent immune suppression, 3. and concurrent bacterial infection.

Interventions

DRUGMoringa oleifera leaf 10mg/100ml

ear drops

DRUGEar Drop

plain ear drop formulation without moringa

Sponsors

Minia University
CollaboratorOTHER
Deraya University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

moringa extract ear drops

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Otomycosis 2. ear inflammation

Exclusion criteria

1. tympanic membrane perforation 2. concurrent immune suppression, 3. concurrent bacterial infection.

Design outcomes

Primary

MeasureTime frameDescription
Number of participants recovered with clear endoscopic examinationone weekNumber of participants recovered with clear endoscopic examination
Identification of different microorganisms infected earup to 1 monthPatients swabs (microorganisms concentration)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026